{"transactions":[{"id":1332181,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T16:15:14.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.4,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-029286","document":"form4-12132024_041207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000141588924029286/form4-12132024_041207.xml","form_type":"4"}},{"id":1691694,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T17:11:50.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.33,"expiration_date":"2033-12-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-24-000461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919124000461/doc4.xml","form_type":"4"}},{"id":1709066,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-15T17:04:11.000Z","date":"2023-12-13","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.7,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-058811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919123058811/doc4.xml","form_type":"4"}},{"id":2186838,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-08-12T17:11:21.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023."}],"balance_after":20500,"derivative":{"exercise_price":0.312,"expiration_date":"2032-08-10","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-22-045650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919122045650/doc4.xml","form_type":"4"}},{"id":2629128,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-07-20T17:05:57.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022."}],"balance_after":20500,"derivative":{"exercise_price":2.75,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-21-047410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919121047410/doc4.xml","form_type":"4"}},{"id":3067229,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-08-05T16:39:06.000Z","date":"2020-08-03","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021."}],"balance_after":22500,"derivative":{"exercise_price":1.72,"expiration_date":"2030-08-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-20-045130","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120045130/doc4.xml","form_type":"4"}},{"id":3180537,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T17:21:32.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":14933,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":135056,"source":{"system":"sec-edgar","filing":"0001209191-20-023803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120023803/doc4.xml","form_type":"4"}},{"id":3180536,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T17:21:32.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":75690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":120123,"source":{"system":"sec-edgar","filing":"0001209191-20-023803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120023803/doc4.xml","form_type":"4"}},{"id":3197817,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-03-23T16:44:54.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":2.67,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-20-020660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120020660/doc4.xml","form_type":"4"}},{"id":3215520,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T17:55:52.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":7321,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":44433,"source":{"system":"sec-edgar","filing":"0001209191-20-018223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120018223/doc4.xml","form_type":"4"}},{"id":3215519,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T17:55:52.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":37112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":37112,"source":{"system":"sec-edgar","filing":"0001209191-20-018223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120018223/doc4.xml","form_type":"4"}},{"id":3215518,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:37:46.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":12360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Foamix restricted stock unit awards (\"Foamix RSUs\") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an \"Adjusted RSU Award\") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120018193/doc4.xml","form_type":"4"}},{"id":3215517,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:37:46.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":62647,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":12360,"source":{"system":"sec-edgar","filing":"0001209191-20-018193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120018193/doc4.xml","form_type":"4"}},{"id":3231724,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-03T16:31:50.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":5312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021."}],"balance_after":75007,"source":{"system":"sec-edgar","filing":"0001209191-20-015193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919120015193/doc4.xml","form_type":"4"}},{"id":3518319,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":85082,"kind":"person","name":"Bruno Anthony D","position":1,"cik":"0001374180","reported_name":"Bruno Anthony D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-20T18:41:11.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":28195,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020."}],"balance_after":69695,"source":{"system":"sec-edgar","filing":"0001209191-19-031534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374180/000120919119031534/doc4.xml","form_type":"4"}}]}